Eritoran tetrasodium

Eritoran tetrasodium is a synthetic lipid A antagonist and a potent inhibitor of Toll-like receptor 4 (TLR4) signaling. Eritoran tetrasodium was developed as a potential therapeutic agent for the treatment of sepsis, a severe and often fatal systemic response to infection characterized by widespread inflammation and organ dysfunction. Despite initial promise in preclinical studies, its development for the treatment of sepsis was halted following the results of a large Phase III clinical trial.

Mechanism of Action

Eritoran tetrasodium works by inhibiting the activation of TLR4, a receptor that plays a crucial role in the innate immune system. TLR4 is activated by lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative bacteria. Activation of TLR4 leads to the production of pro-inflammatory cytokines, which are important for fighting infections but can cause severe damage to the host if produced in excess. By blocking TLR4 activation, eritoran tetrasodium aims to prevent the excessive inflammatory response associated with sepsis.

Clinical Development

The development of eritoran tetrasodium for the treatment of sepsis was based on the hypothesis that modulating the host's immune response to infection could improve outcomes. The most significant clinical trial evaluating eritoran tetrasodium was the ACCESS (A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis) trial. This Phase III study aimed to assess the efficacy and safety of eritoran tetrasodium in reducing mortality in patients with severe sepsis. Unfortunately, the trial did not meet its primary endpoint of a significant reduction in 28-day all-cause mortality among patients treated with eritoran tetrasodium compared to those receiving placebo.

Implications and Future Directions

The failure of the ACCESS trial was a significant setback for the development of TLR4 inhibitors for sepsis. However, the study of eritoran tetrasodium has contributed valuable insights into the pathophysiology of sepsis and the role of the innate immune system in this condition. Research into TLR4 and its signaling pathways continues, with the hope that new therapeutic targets may emerge for the treatment of sepsis and other inflammatory diseases.

See Also

• Sepsis
• Toll-like receptor
• Innate immune system
• Cytokine
• Gram-negative bacteria

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian